Latest Strategy News

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.

Flagship Minerals has identified six new copper targets through a stream sediment survey at its Rosario Copper Project in Chile, with three targets ranked as high priority, confirming extensive copper mineralisation across the site.

Mach7 Technologies has initiated a A$5 million on-market share buy-back program, reflecting confidence in its robust financial health and growth outlook. The move underscores the company’s commitment to capital management amid reaffirmed FY25 revenue growth guidance.

Austral Gold reported an 8.5% production increase in Q4 2024 alongside significant cost reductions, though full-year output fell short of forecasts due to equipment delays. The company sets ambitious 2025 targets, supported by a new toll processing deal and plant refurbishment financing.

Australian Strategic Materials (ASM) has secured a $5 million federal grant to accelerate its Dubbo Project, progressing rare earth recovery innovations while navigating a complex global market landscape.

Buxton Resources reports robust drilling results at its Graphite Bull and Narryer projects, completes Stage 1 earn-in on Copper Wolf JV with IGO, and undertakes key board changes, positioning itself for an active 2025 exploration season.

Delta Lithium reports robust December quarter results with significant gold drilling successes at Mt Ida and progress on lithium development at Yinnetharra, alongside strategic leadership changes and asset sales.

Uvre Limited has completed a key Phase 2 geophysical survey at its Frome Downs Uranium Project in South Australia and secured a Heritage Survey Agreement, setting the stage for its inaugural drilling program.

Asset Vision Co Limited has reported a robust Q2 FY25, marked by significant revenue growth, improved cash flow, and effective cost management, positioning the company well for continued expansion.

Perpetual Limited's Q2 FY25 update reveals a 3.6% rise in Assets Under Management to A$230.2 billion, buoyed by currency tailwinds despite net outflows and market headwinds. Corporate Trust and Wealth Management also posted modest growth, setting the stage for the upcoming half-year results.

Gold Mountain Limited reports strong exploration progress across its Brazilian lithium, rare earth, and copper projects, highlighted by high-grade drill results and expanding target pipelines.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.